Leonteq Securities AG Sells 16,391 Shares of DexCom, Inc. $DXCM

Leonteq Securities AG trimmed its holdings in DexCom, Inc. (NASDAQ:DXCM) by 51.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,574 shares of the medical device company’s stock after selling 16,391 shares during the period. Leonteq Securities AG’s holdings in DexCom were worth $978,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Trust Co. of Vermont boosted its holdings in shares of DexCom by 14.8% in the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock worth $74,000 after acquiring an additional 145 shares during the period. CVA Family Office LLC raised its stake in shares of DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 147 shares during the period. Essex Financial Services Inc. lifted its holdings in DexCom by 5.7% during the 1st quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock worth $204,000 after purchasing an additional 175 shares in the last quarter. IFP Advisors Inc lifted its holdings in DexCom by 24.7% during the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after purchasing an additional 178 shares in the last quarter. Finally, Keel Point LLC boosted its stake in DexCom by 3.1% in the 4th quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock worth $430,000 after purchasing an additional 193 shares during the period. Institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on DXCM. Robert W. Baird set a $80.00 target price on DexCom in a report on Friday, May 1st. Weiss Ratings restated a “hold (c-)” rating on shares of DexCom in a research report on Monday, June 1st. Benchmark reaffirmed a “buy” rating on shares of DexCom in a research note on Tuesday, June 23rd. Raymond James Financial reaffirmed a “strong-buy” rating and set a $91.00 target price on shares of DexCom in a report on Monday, June 8th. Finally, Evercore raised shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price target for the company in a report on Tuesday, March 24th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $84.88.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $71.25 on Friday. The stock’s 50-day simple moving average is $68.31 and its two-hundred day simple moving average is $68.17. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98. The firm has a market capitalization of $27.49 billion, a P/E ratio of 30.45, a P/E/G ratio of 1.17 and a beta of 1.45. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter last year, the company posted $0.32 EPS. The company’s revenue for the quarter was up 15.0% on a year-over-year basis. As a group, equities analysts anticipate that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Kevin R. Sayer sold 26,759 shares of the stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total value of $1,926,648.00. Following the transaction, the insider owned 382,482 shares of the company’s stock, valued at $27,538,704. This represents a 6.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,911 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $74.13, for a total transaction of $364,052.43. Following the sale, the executive vice president owned 95,450 shares in the company, valued at approximately $7,075,708.50. This trade represents a 4.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 46,694 shares of company stock valued at $3,343,977 over the last three months. Corporate insiders own 0.28% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.